BeOne Medicines revenue and financials
$362.78Change from previous close: +0.31%Absolute change: +$1.13
In the fiscal year ended December 2025, BeOne Medicines reported revenue of $5.34B (+40.23% year over year). Net income was $286.93M, a net margin of 5.4%.
Fiscal year ending in December. Sources and method on the page Methodology and sources.
At a glance
- Revenue growth
- +40.23%
- 2025 vs 2024
- Net margin
- 5.4%
- 2024: -16.9%
Financial data
Amounts in millions of USD; per-share values in USD; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 1,128 | -141 | -1,157 | -1,497 | -1,299 | -1,283 | -750 | -548 | 12.8 | -89.5 |
| Depreciation and amortization | 142 | 172 | 87.7 | 66.3 | 46.5 | 31.8 | 18.6 | 10.4 | 4.8 | 1.9 |
| Capital expenditure | -186 | -493 | -562 | -325 | -263 | -118 | -89.6 | -70.3 | -46.4 | -23.5 |
| Investing cash flow | -276 | -548 | 60.0 | 1,077 | 641 | — | — | — | — | — |
| Financing cash flow | 1,059 | 193 | 416 | -19.0 | 3,637 | — | — | — | — | — |
| Share repurchases | -24.2 | — | — | — | — | — | — | — | — | — |
| Debt issued | 1,084 | 877 | 684 | 351 | 423 | — | — | — | — | — |
| Debt repaid | -1,080 | -732 | -323 | -417 | -322 | — | — | — | — | — |
| Effect of exchange rates | 60.0 | -51.7 | -8.1 | -69.4 | 14.0 | — | — | — | — | — |
| Net change in cash | 1,971 | -547 | -689 | -508 | 2,993 | — | — | — | — | — |
| Free cash flow | 942 | -633 | -1,719 | -1,822 | -1,562 | — | — | — | — | — |
| Levered free cash flow | 656 | -371 | -1,274 | -944 | -1,204 | — | — | — | — | — |